About Us

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...
 
 

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS

SPHINGOTEC GROUP

COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY

sphingotec
NexusDX

 

LATEST NEWS

  • sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)

    sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)

  • sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology

    sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology

  • Endothelial disruption: Rapid translation from bench to bedside 

    Endothelial disruption: Rapid translation from bench to bedside 

  • sphingotec raises €20 million from HBM and Wellington Partners

    sphingotec raises €20 million from HBM and Wellington Partners

previous arrow
next arrow
Slider

 

BIOMARKER

Sphingotest penKid
sphingotest® penKid®
Sphingotest bio-ADM
sphingotest® bio-ADM®

 
 

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS

 
 

OUR PARTNERS

 

Top